Literature DB >> 19965671

Molecular signatures to improve diagnosis in peripheral T-cell lymphoma and prognostication in angioimmunoblastic T-cell lymphoma.

Javeed Iqbal1, Dennis D Weisenburger, Timothy C Greiner, Julie M Vose, Timothy McKeithan, Can Kucuk, Huimin Geng, Karen Deffenbacher, Lynette Smith, Karen Dybkaer, Shigeo Nakamura, Masao Seto, Jan Delabie, Francoise Berger, Florence Loong, Wing Y Au, Young-Hyeh Ko, Ivy Sng, James Olen Armitage, Wing C Chan.   

Abstract

Peripheral T-cell lymphoma (PTCL) is often challenging to diagnose and classify. Gene expression profiling was performed on 144 cases of PTCL and natural killer cell lymphoma and robust molecular classifiers were constructed for angioimmunoblastic T-cell lymphoma (AITL), anaplastic lymphoma kinase-positive (ALK(+)) anaplastic large-cell lymphoma (ALCL), and adult T-cell leukemia/lymphoma. PTCL-unclassifiable was molecularly heterogeneous, but we were able to identify a molecular subgroup with features of cytotoxic T lymphocytes and a poor survival compared with the remaining PTCL-not otherwise specified cases. Many of the pathologic features and substantial components of the molecular signature of AITL are contributed by the follicular dendritic cells, B-cell, and other stromal components. The expression of Th17-associated molecules in ALK(+) ALCL was noted and may represent aberrant activation of Th17-cell differentiation by abnormal cytokine secretion. Adult T-cell leukemia/lymphoma has a homogeneous molecular signature demonstrating high expression of human T-lymphotropic virus type 1-induced genes. These classifiers reflect the biology of the tumor cells as well as their microenvironment. We also constructed a molecular prognosticator for AITL that appears to be largely related to the microenvironmental signature, and the high expression of 2 immunosuppressive signatures are associated with poor outcome. Oncogenic pathways and tumor-host interactions also were identified, and these findings may lead to better therapies and outcome in the future.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19965671      PMCID: PMC2817630          DOI: 10.1182/blood-2009-06-227579

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  61 in total

1.  Significance analysis of microarrays applied to the ionizing radiation response.

Authors:  V G Tusher; R Tibshirani; G Chu
Journal:  Proc Natl Acad Sci U S A       Date:  2001-04-17       Impact factor: 11.205

Review 2.  Expression of cytotoxic proteins in peripheral T-cell and natural killer-cell (NK) lymphomas: association with extranodal site, NK or Tgammadelta phenotype, anaplastic morphology and CD30 expression.

Authors:  P Kanavaros; M L Boulland; B Petit; B Arnulf; P Gaulard
Journal:  Leuk Lymphoma       Date:  2000-07

3.  Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study.

Authors:  Andrea Gallamini; Caterina Stelitano; Roberta Calvi; Monica Bellei; Daniele Mattei; Umberto Vitolo; Fortunato Morabito; Maurizio Martelli; Ercole Brusamolino; Emilio Iannitto; Francesco Zaja; Sergio Cortelazzo; Luigi Rigacci; Liliana Devizzi; Giuseppe Todeschini; Gino Santini; Maura Brugiatelli; Massimo Federico
Journal:  Blood       Date:  2003-11-26       Impact factor: 22.113

4.  T follicular helper cells express a distinctive transcriptional profile, reflecting their role as non-Th1/Th2 effector cells that provide help for B cells.

Authors:  Tatyana Chtanova; Stuart G Tangye; Rebecca Newton; Nita Frank; Martin R Hodge; Michael S Rolph; Charles R Mackay
Journal:  J Immunol       Date:  2004-07-01       Impact factor: 5.422

5.  Unique gene expression program of human germinal center T helper cells.

Authors:  Chang H Kim; Hyung W Lim; Jong R Kim; Lusijah Rott; Peter Hillsamer; Eugene C Butcher
Journal:  Blood       Date:  2004-06-22       Impact factor: 22.113

6.  Neoplastic T cells in angioimmunoblastic T-cell lymphoma express CD10.

Authors:  Ayoma Attygalle; Rajai Al-Jehani; Tim C Diss; Phillipa Munson; Hongxiang Liu; Ming-Qing Du; Peter G Isaacson; Ahmet Dogan
Journal:  Blood       Date:  2002-01-15       Impact factor: 22.113

7.  Cutting edge: IL-21 is a switch factor for the production of IgG1 and IgG3 by human B cells.

Authors:  Jérôme Pène; Jean-François Gauchat; Sandrine Lécart; Elodie Drouet; Paul Guglielmi; Vera Boulay; Adriana Delwail; Don Foster; Jean-Claude Lecron; Hans Yssel
Journal:  J Immunol       Date:  2004-05-01       Impact factor: 5.422

8.  Cutting edge: IL-26 signals through a novel receptor complex composed of IL-20 receptor 1 and IL-10 receptor 2.

Authors:  Faruk Sheikh; Vitaliy V Baurin; Anita Lewis-Antes; Nital K Shah; Sergey V Smirnov; Shubha Anantha; Harold Dickensheets; Laure Dumoutier; Jean-Christophe Renauld; Alexander Zdanov; Raymond P Donnelly; Sergei V Kotenko
Journal:  J Immunol       Date:  2004-02-15       Impact factor: 5.422

9.  Classification of distinct subtypes of peripheral T-cell lymphoma unspecified, identified by chemokine and chemokine receptor expression: Analysis of prognosis.

Authors:  Koichi Ohshima; Kennosuke Karube; Riko Kawano; Takeshi Tsuchiya; Hiroaki Suefuji; Takahiro Yamaguchi; Junji Suzumiya; Masahiro Kikuchii
Journal:  Int J Oncol       Date:  2004-09       Impact factor: 5.650

10.  Semi-supervised methods to predict patient survival from gene expression data.

Authors:  Eric Bair; Robert Tibshirani
Journal:  PLoS Biol       Date:  2004-04-13       Impact factor: 8.029

View more
  116 in total

1.  Expression of the chemokine receptor gene, CCR8, is associated With DUSP22 rearrangements in anaplastic large cell lymphoma.

Authors:  Xiaoming Xing; Thomas J Flotte; Mark E Law; Anthony J Blahnik; Wee-Joo Chng; Gaofeng Huang; Ryan A Knudson; Rhett P Ketterling; Julie C Porcher; Stephen M Ansell; Jagmohan Sidhu; Ahmet Dogan; Andrew L Feldman
Journal:  Appl Immunohistochem Mol Morphol       Date:  2015-09

2.  Genome-wide miRNA profiling of mantle cell lymphoma reveals a distinct subgroup with poor prognosis.

Authors:  Javeed Iqbal; Yulei Shen; Yanyan Liu; Kai Fu; Elaine S Jaffe; Cuiling Liu; Zhongfeng Liu; Cynthia M Lachel; Karen Deffenbacher; Timothy C Greiner; Julie M Vose; Sharathkumar Bhagavathi; Louis M Staudt; Lisa Rimsza; Andreas Rosenwald; German Ott; Jan Delabie; Elias Campo; Rita M Braziel; James R Cook; Raymond R Tubbs; Randy D Gascoyne; James O Armitage; Dennis D Weisenburger; Timothy W McKeithan; Wing C Chan
Journal:  Blood       Date:  2012-04-05       Impact factor: 22.113

Review 3.  Should eligible patients with T-cell lymphoma receive high-dose therapy and autologous stem cell transplant in the upfront setting?

Authors:  Carla Casulo; Steven Horwitz
Journal:  Curr Oncol Rep       Date:  2010-11       Impact factor: 5.075

Review 4.  New strategies in peripheral T-cell lymphoma: understanding tumor biology and developing novel therapies.

Authors:  Kieron Dunleavy; Richard L Piekarz; Jasmine Zain; John E Janik; Wyndham H Wilson; Owen A O'Connor; Susan E Bates
Journal:  Clin Cancer Res       Date:  2010-12-01       Impact factor: 12.531

Review 5.  Update: peripheral T-cell lymphomas.

Authors:  Kerry J Savage
Journal:  Curr Hematol Malig Rep       Date:  2011-12       Impact factor: 3.952

6.  Enforced expression of Lin28b leads to impaired T-cell development, release of inflammatory cytokines, and peripheral T-cell lymphoma.

Authors:  Sarah H Beachy; Masahiro Onozawa; Yang Jo Chung; Chris Slape; Sven Bilke; Princy Francis; Marbin Pineda; Robert L Walker; Paul Meltzer; Peter D Aplan
Journal:  Blood       Date:  2012-06-21       Impact factor: 22.113

7.  Recurrent activating mutations of CD28 in peripheral T-cell lymphomas.

Authors:  J Rohr; S Guo; J Huo; A Bouska; C Lachel; Y Li; P D Simone; W Zhang; Q Gong; C Wang; A Cannon; T Heavican; A Mottok; S Hung; A Rosenwald; R Gascoyne; K Fu; T C Greiner; D D Weisenburger; J M Vose; L M Staudt; W Xiao; G E O Borgstahl; S Davis; C Steidl; T McKeithan; J Iqbal; W C Chan
Journal:  Leukemia       Date:  2015-12-31       Impact factor: 11.528

8.  A phase II study of cyclophosphamide, etoposide, vincristine and prednisone (CEOP) Alternating with Pralatrexate (P) as front line therapy for patients with peripheral T-cell lymphoma (PTCL): final results from the T- cell consortium trial.

Authors:  Ranjana H Advani; Stephen M Ansell; Mary J Lechowicz; Anne W Beaven; Fausto Loberiza; Kenneth R Carson; Andrew M Evens; Francine Foss; Steven Horwitz; Barbara Pro; Lauren C Pinter-Brown; Sonali M Smith; Andrei R Shustov; Kerry J Savage; Julie M Vose
Journal:  Br J Haematol       Date:  2015-12-02       Impact factor: 6.998

9.  A novel role for IL-22R1 as a driver of inflammation.

Authors:  Ram Savan; Adelle P McFarland; Della A Reynolds; Lionel Feigenbaum; Karthika Ramakrishnan; Megan Karwan; Hidekazu Shirota; Dennis M Klinman; Kieron Dunleavy; Stefania Pittaluga; Stephen K Anderson; Raymond P Donnelly; Wyndham H Wilson; Howard A Young
Journal:  Blood       Date:  2010-10-22       Impact factor: 22.113

Review 10.  Peripheral T cell lymphomas: from the bench to the clinic.

Authors:  Danilo Fiore; Luca Vincenzo Cappelli; Alessandro Broccoli; Pier Luigi Zinzani; Wing C Chan; Giorgio Inghirami
Journal:  Nat Rev Cancer       Date:  2020-04-06       Impact factor: 60.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.